Journal of Diabetes Investigation最新文献

{"title":"Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity","authors":"Wanlu Ma,&nbsp;Bo Zhang,&nbsp;Xiaoping Chen","doi":"10.1111/jdi.14372","DOIUrl":"10.1111/jdi.14372","url":null,"abstract":"<p>We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"357-359"},"PeriodicalIF":3.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximum insulin dose in patients admitted to the intensive care units with severe COVID-19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study","authors":"Emi Ushigome,&nbsp;Dan Imai,&nbsp;Masahide Hamaguchi,&nbsp;Satoru Hashimoto,&nbsp;Michiaki Fukui","doi":"10.1111/jdi.14380","DOIUrl":"10.1111/jdi.14380","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to determine the maximum daily insulin dose (MDI) and associated factors in critically ill patients with coronavirus disease 2019 (COVID-19) receiving insulin therapy, under ventilator and/or extracorporeal membrane oxygenation (ECMO) management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This cross-sectional analysis used the Cross ICU Searchable Information System data from a Japanese multicenter retrospective observational cohort study of critically ill patients with COVID-19 receiving ventilation and/or ECMO, from February 2020 to March 2022. Maximum daily insulin dose was determined, and factors associated with it and maximum daily insulin dose per body weight were assessed using linear regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis included 788 patients. Their mean age, glycated hemoglobin level, maximum daily insulin dose, and time from admission to the maximum daily insulin dose were 65.2 ± 13.0 years, 7.0 ± 1.5% (53.0 ± 7.1 mmol/mol), 46.0 ± 43.6 U/day, and 7.3 ± 7.0 days, respectively. Male sex (β = 6.902, <i>P</i> = 0.034), body mass index (β = 1.020, <i>P</i> = 0.001), glycated hemoglobin (β = 12.272, <i>P</i> &lt; 0.001), and having renal failure (β = 20.637, <i>P</i> = 0.003) were independent determinants of maximum daily insulin dose. Age (β = 0.004, <i>P</i> = 0.035), glycated hemoglobin (β = 0.154, <i>P</i> &lt; 0.001), and having renal failure (β = 0.282, <i>P</i> = 0.004) were independent determinants of maximum daily insulin dose per body weight.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with COVID-19 on ventilator and/or ECMO management, the maximum daily insulin dose reached after about 1 week of hospitalization was approximately 46.0 U/day. Glycated hemoglobin and renal failure were both associated with the maximum daily insulin dose and maximum daily insulin dose per body weight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"555-560"},"PeriodicalIF":3.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus","authors":"Zhuangsen Chen,&nbsp;Zhongyu Zhou,&nbsp;Lin Wang,&nbsp;Yanrong Zhang,&nbsp;Caiyan Huang,&nbsp;Cong Wang,&nbsp;Ying Huang,&nbsp;Shanshan Wang,&nbsp;Dewen Yan,&nbsp;Kun Feng","doi":"10.1111/jdi.14373","DOIUrl":"10.1111/jdi.14373","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Polyethylene glycol loxenatide (PEG-Loxe) is applied in treating type 2 diabetes mellitus. Nevertheless, the effect and mechanism of PEG-Loxe on lipid metabolism disorder and insulin resistance in type 2 diabetes mellitus are not fully understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Type 2 diabetes mellitus rats developed by high-fat diet/streptozotocin injection were treated with PEG-Loxe (0.3 or 1 mg/kg). Insulin resistance was evaluated by fasting blood glucose (FBG), oral glucose tolerance test, fasting insulin, homeostasis model of assessment for insulin resistance and for insulin sensitivity. Immunohistochemistry, hematoxylin and eosin staining, and biochemistry measurements were performed to assess lipid metabolism. Inflammatory response and oxidative stress were assessed by inflammatory cytokines and reactive oxygen species. Genes’ expressions were tested using RT-qPCR, western blot, and in situ hybridization. Relationships of molecules were validated by pull-down assay and RNA immunoprecipitation. mRNA stability was examined by actinomycin D assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>High-PEG-Loxe decreased FBG and ameliorated glucose tolerance, hyperinsulinemia, and insulin resistance. Low-PEG-Loxe partly while high-PEG-Loxe apparently relieved hepatocyte injury, reduced lipase I, triglyceride, total cholesterol and leptin, and increased adiponectin in type 2 diabetes mellitus rats. PEG-Loxe mitigated inflammatory response and oxidative stress. High-PEG-Loxe reduced RhoA and Rho-associated coiled-coil kinase 2 (ROCK2) in liver tissues of type 2 diabetes mellitus rats, while both doses of PEG-Loxe decreased steroid receptor RNA activator (SRA). SRA overexpression reversed the protective functions of high-PEG-Loxe. SRA cooperated with cellular nucleic acid binding protein (CNBP) to enhance ROCK2 mRNA stability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>High-PEG-Loxe relieves insulin resistance and lipid metabolism disorder in type 2 diabetes mellitus through SRA/CNBP/ROCK2 axis. This research provides a molecular mechanism of PEG-Loxe for treating type 2 diabetes mellitus.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 4","pages":"715-727"},"PeriodicalIF":3.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14373","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA and transcriptome profiling in pregnant women with diabetes","authors":"Rafal Sibiak,&nbsp;Pawel Gutaj,&nbsp;Urszula Mantaj,&nbsp;Lukasz Adamczak,&nbsp;Malgorzata Blatkiewicz,&nbsp;Marcin Rucinski,&nbsp;Ewa Wender-Ozegowska","doi":"10.1111/jdi.14369","DOIUrl":"10.1111/jdi.14369","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Placental glucose transport is regulated by glucose transporter proteins (GLUTs). The study aimed to examine placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA in patients with type 1 diabetes, early gestational diabetes (eGDM), and healthy controls, and to investigate correlations between GLUTs expression and clinical parameters. Additionally, we compared placental transcriptome profiles in recruited subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We recruited 59 pregnant women: 23 with type 1 diabetes, 17 with eGDM, and 19 controls. Patients with diabetes attended follow-up visits at each trimester. Transcriptome studies were performed in 4 patients per subgroup.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age was similar across all subgroups. eGDM patients had significantly higher BMI and were predominantly obese. We observed a significant 2-fold (<i>P</i> = 0.009) decrease in placental GLUT-3 mRNA expression in the type 1 diabetes and eGDM groups. GLUT-4 mRNA expression was significantly lower in the eGDM group compared to type 1 diabetes (3-fold) and controls (6-fold) (<i>P</i> = 0.007). There was a significant negative correlation between GLUT-3 (<i>R</i> = −0.29) and GLUT-4 (<i>R</i> = −0.27) mRNA expression and neonatal birth weight. GLUT-4 expression was negatively correlated with 1st trimester HbA1c (<i>R</i> = −0.72) and OGTT 120′ (<i>R</i> = −0.82) results in eGDM patients, and 3rd trimester glycemic variability (<i>R</i> = −0.49) in type 1 diabetes. Microarray analysis revealed significant transcriptomic changes, with 45 down-regulated and 365 up-regulated genes in type 1 diabetes, and 21 significant changes in eGDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Placental samples from patients with diabetes exhibit changes in GLUTs expression, which correlates with neonatal growth and several glycemic parameters. Additionally, multiple changes in transcriptomic profiles are observed in hyperglycemic patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"543-554"},"PeriodicalIF":3.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14369","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume 15","authors":"","doi":"10.1111/jdi.14374","DOIUrl":"https://doi.org/10.1111/jdi.14374","url":null,"abstract":"&lt;p&gt;50-g Oral glucose challenge test&lt;/p&gt;&lt;p&gt;Problems in screening for gestational diabetes mellitus by measurement of casual blood glucose levels at 24–28 gestational weeks, Tomimoto 1797–1802.&lt;/p&gt;&lt;p&gt;β-Cell dysfunction&lt;/p&gt;&lt;p&gt;Glucose metabolism partially regulates β-cell function through epigenomic changes, Kim 649–655.&lt;/p&gt;&lt;p&gt;β-Cells&lt;/p&gt;&lt;p&gt;Role of β-cell autophagy in β-cell physiology and the development of diabetes, Yasasilka 656–668.&lt;/p&gt;&lt;p&gt;β-Cell mass&lt;/p&gt;&lt;p&gt;Effects of glucokinase haploinsufficiency on the pancreatic β-cell mass and function of long-term high-fat, high-sucrose diet-fed mice, Shigesawa 1732–1742.&lt;/p&gt;&lt;p&gt;Accuracy&lt;/p&gt;&lt;p&gt;Impact of hematocrit levels on the accuracy of specific blood glucose meters: A hospital-based study, Pham 1472–1482.&lt;/p&gt;&lt;p&gt;Acyl-coenzyme A synthetase long-chain family member 4&lt;/p&gt;&lt;p&gt;Tanshinone IIA suppresses ferroptosis to attenuate renal podocyte injury in diabetic nephropathy through the embryonic lethal abnormal visual-like protein 1 and acyl-coenzyme A synthetase long-chain family member 4 signaling pathway, Zhu 1003–1016.&lt;/p&gt;&lt;p&gt;Adherence&lt;/p&gt;&lt;p&gt;Modification effect of receipt of diabetes care on the association between COVID-19 infection and HbA1c level during the first year of the coronavirus pandemic using a nationwide population-based database, Okada 953–963.&lt;/p&gt;&lt;p&gt;Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: A systematic review and meta-analysis, Boonpattharatthiti 1614–1625.&lt;/p&gt;&lt;p&gt;Aging&lt;/p&gt;&lt;p&gt;Association of biomarkers and Barthel Index with occurrence of age-related adverse health outcomes in individuals with diabetes, Umamoto 1675–1683.&lt;/p&gt;&lt;p&gt;Alcohol drinking&lt;/p&gt;&lt;p&gt;The association between alcohol drinking and glycemic management among people with type 2 diabetes in China, Ye 237–244.&lt;/p&gt;&lt;p&gt;Aldehyde dehydrogenase 2&lt;/p&gt;&lt;p&gt;Mitochondrial ALDH2 improves β-cell survival and function against doxorubicin-induced apoptosis by targeting CK2 signaling, Karunakaran 684–692.&lt;/p&gt;&lt;p&gt;Algorithm&lt;/p&gt;&lt;p&gt;A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd edition (English version), Bouchi 1326–1342.&lt;/p&gt;&lt;p&gt;Alzheimer's disease-like complications of DM&lt;/p&gt;&lt;p&gt;Calpeptin improves the cognitive function in Alzheimer's disease-like complications of diabetes mellitus rats by regulating TXNIP/NLRP3 inflammasome, Qiao 1365–1376.&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4 is a potential biomarker for diabetic kidney disease in type 2 diabetes patients, Wang 1763–1772.&lt;/p&gt;&lt;p&gt;Antidiabetic drugs&lt;/p&gt;&lt;p&gt;Cancer biology in diabetes update: Focusing on antidiabetic drugs, Kawakita 525–540.&lt;/p&gt;&lt;p&gt;Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes, Moon 669–683.&lt;/p&gt;&lt;p&gt;Anti-inflammatory activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabetes: Structural and functional relevance, Lui 805–816.&lt;/p&gt;&lt;p&gt;Anti-oxidative activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabete","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1841-1861"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"10.1111/jdi.14324","DOIUrl":"https://doi.org/10.1111/jdi.14324","url":null,"abstract":"&lt;p&gt;The publication of invaluable papers in the Journal of Diabetes Investigation depends on the prompt, careful review of submitted manuscripts. We would like to thank the Editorial Board members, the International Editorial Board members, the Assistant Editorial Board members and the following experts for reviewing manuscripts from September 1, 2023 to August 31, 2024.&lt;/p&gt;&lt;p&gt;Mohammed S. Abusamaan&lt;/p&gt;&lt;p&gt;Adegbenga B. Ademolu&lt;/p&gt;&lt;p&gt;Houssein Ahmadi&lt;/p&gt;&lt;p&gt;Zubair Ahmed&lt;/p&gt;&lt;p&gt;Ken-Ichi Aihara&lt;/p&gt;&lt;p&gt;Yoichi Ajiro&lt;/p&gt;&lt;p&gt;Satoru Akazawa&lt;/p&gt;&lt;p&gt;Hamed Akbari&lt;/p&gt;&lt;p&gt;Gulali Aktas&lt;/p&gt;&lt;p&gt;Nurshad Ali&lt;/p&gt;&lt;p&gt;Shigeru Aoki&lt;/p&gt;&lt;p&gt;Tomohisa Aoyama&lt;/p&gt;&lt;p&gt;Keiko Arai&lt;/p&gt;&lt;p&gt;Atsushi Araki&lt;/p&gt;&lt;p&gt;Osamu Arisaka&lt;/p&gt;&lt;p&gt;Shunichiro Asahara&lt;/p&gt;&lt;p&gt;Kenji Ashida&lt;/p&gt;&lt;p&gt;Yoshimasa Aso&lt;/p&gt;&lt;p&gt;Hande Atalay&lt;/p&gt;&lt;p&gt;Ahmad Khusairi Azemi&lt;/p&gt;&lt;p&gt;Kengo Azushima&lt;/p&gt;&lt;p&gt;Masayuki Baba&lt;/p&gt;&lt;p&gt;Asaad Ma Babker&lt;/p&gt;&lt;p&gt;Mohamed F. Balaha&lt;/p&gt;&lt;p&gt;Ryotaro Bouchi&lt;/p&gt;&lt;p&gt;David S. Boyer&lt;/p&gt;&lt;p&gt;Ali Cetin&lt;/p&gt;&lt;p&gt;Chi-Ming Chan&lt;/p&gt;&lt;p&gt;Te-Fu Chan&lt;/p&gt;&lt;p&gt;Min-Cheol Chang&lt;/p&gt;&lt;p&gt;Deqing Chen&lt;/p&gt;&lt;p&gt;Deyan Chen&lt;/p&gt;&lt;p&gt;Harn-Shen Chen&lt;/p&gt;&lt;p&gt;Juncao Chen&lt;/p&gt;&lt;p&gt;Ming-Wei Chen&lt;/p&gt;&lt;p&gt;Yang Ching Chen&lt;/p&gt;&lt;p&gt;Yen-Lin Chen&lt;/p&gt;&lt;p&gt;Yi-Rong Chen&lt;/p&gt;&lt;p&gt;Kenneth Cheng&lt;/p&gt;&lt;p&gt;Kyu Yong Cho&lt;/p&gt;&lt;p&gt;Soo Choi&lt;/p&gt;&lt;p&gt;Chih-Hsun Chu&lt;/p&gt;&lt;p&gt;Daisuke Chujo&lt;/p&gt;&lt;p&gt;Seung Min Chung&lt;/p&gt;&lt;p&gt;Dana Mihaela Ciobanu&lt;/p&gt;&lt;p&gt;Flávia Campos Corgosinho&lt;/p&gt;&lt;p&gt;Andre Luiz Costa&lt;/p&gt;&lt;p&gt;Xiaona Cui&lt;/p&gt;&lt;p&gt;Makoto Daimon&lt;/p&gt;&lt;p&gt;Taura Daisuke&lt;/p&gt;&lt;p&gt;Undurti Das&lt;/p&gt;&lt;p&gt;Takahisa Deguchi&lt;/p&gt;&lt;p&gt;Masashi Demura&lt;/p&gt;&lt;p&gt;Wuquan Deng&lt;/p&gt;&lt;p&gt;Sunil Deshpande&lt;/p&gt;&lt;p&gt;Domenico Di Raimondo&lt;/p&gt;&lt;p&gt;Yu Ding&lt;/p&gt;&lt;p&gt;Kentaro Doi&lt;/p&gt;&lt;p&gt;Jocelyn J. Drinkwater&lt;/p&gt;&lt;p&gt;Joao M. N. Duarte&lt;/p&gt;&lt;p&gt;Tuba Duman&lt;/p&gt;&lt;p&gt;Jun Eguchi&lt;/p&gt;&lt;p&gt;Akira Endo&lt;/p&gt;&lt;p&gt;Kang-Chih Fan&lt;/p&gt;&lt;p&gt;Lei Feng&lt;/p&gt;&lt;p&gt;Gabor Ferneisz&lt;/p&gt;&lt;p&gt;Chia-Po Fu&lt;/p&gt;&lt;p&gt;Toshihito Fujii&lt;/p&gt;&lt;p&gt;Rumi Fujikawa&lt;/p&gt;&lt;p&gt;Junji Fujikura&lt;/p&gt;&lt;p&gt;Shimpei Fujimoto&lt;/p&gt;&lt;p&gt;Shiho Fujisaka&lt;/p&gt;&lt;p&gt;Yoshihito Fujita&lt;/p&gt;&lt;p&gt;Yukihiro Fujita&lt;/p&gt;&lt;p&gt;Yoshio Fujitani&lt;/p&gt;&lt;p&gt;Michiaki Fukui&lt;/p&gt;&lt;p&gt;Masato Furuhashi&lt;/p&gt;&lt;p&gt;Shinya Furukawa&lt;/p&gt;&lt;p&gt;Hiroto Furuta&lt;/p&gt;&lt;p&gt;Yechiel N. Gellman&lt;/p&gt;&lt;p&gt;Stacey Gorniak&lt;/p&gt;&lt;p&gt;Atsushi Goto&lt;/p&gt;&lt;p&gt;Weaam Gouda&lt;/p&gt;&lt;p&gt;Alpesh Goyal&lt;/p&gt;&lt;p&gt;Tanja Groten&lt;/p&gt;&lt;p&gt;Xuejiang Gu&lt;/p&gt;&lt;p&gt;Yunjuan Gu&lt;/p&gt;&lt;p&gt;Keyu Guo&lt;/p&gt;&lt;p&gt;Kyoung Hwa Ha&lt;/p&gt;&lt;p&gt;Masahide Hamaguchi&lt;/p&gt;&lt;p&gt;Akihiro Hamasaki&lt;/p&gt;&lt;p&gt;Toshiaki Hanafusa&lt;/p&gt;&lt;p&gt;Rikinari Hanayama&lt;/p&gt;&lt;p&gt;Shinichi Harashima&lt;/p&gt;&lt;p&gt;Goji Hasegawa&lt;/p&gt;&lt;p&gt;Koshi Hashimoto&lt;/p&gt;&lt;p&gt;Yoshitaka Hashimoto&lt;/p&gt;&lt;p&gt;Nabil A. Hasona&lt;/p&gt;&lt;p&gt;Yuji Hataya&lt;/p&gt;&lt;p&gt;Yoshitaka Hayashi&lt;/p&gt;&lt;p&gt;Yasuaki Hayashino&lt;/p&gt;&lt;p&gt;Sakoda Hideyuki&lt;/p&gt;&lt;p&gt;Shinji Higuchi&lt;/p&gt;&lt;p&gt;Tatsuhito Himeno&lt;/p&gt;&lt;p&gt;Tsutomu Hirano&lt;/p&gt;&lt;p&gt;Satoshi Hirayama&lt;/p&gt;&lt;p&gt;Takahisa Hirose&lt;/p&gt;&lt;p&gt;Inoue Hiroshi&lt;/p&gt;&lt;p&gt;Yushi Hirota&lt;/p&gt;&lt;p&gt;Takanori Honda&lt;/p&gt;&lt;p&gt;Minha Hong&lt;/p&gt;&lt;p&gt;Ruby Hoo&lt;/p&gt;&lt;p&gt;Ichiro Horie&lt;/p&gt;&lt;p&gt;Takeshi Horii&lt;/p&gt;&lt;p&gt;Yukio Horikawa&lt;/p&gt;&lt;p&gt;Masayuki Hosoi&lt;/p&gt;&lt;p&gt;Yi-Ting Hsieh&lt;/p&gt;&lt;p&gt;Paul Hsu&lt;/p&gt;&lt;p&gt;Cheng Hu&lt;/p&gt;&lt;p&gt;Haofei Hu&lt;/p&gt;&lt;p&gt;Chia-Luen Huang&lt;/p&gt;&lt;p&gt;Chuiguo Huang&lt;/p&gt;&lt;p&gt;Cn Huang&lt;/p&gt;&lt;p&gt;Yu-Tung Huang&lt;/p&gt;&lt;p&gt;Zhimin Huang&lt;/p&gt;&lt;p&gt;Mikael S Huhtala&lt;/p&gt;&lt;p&gt;Sartaj Hussain&lt;/p&gt;&lt;p&gt;You-Cheol H","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1838-1840"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of universal screening for gestational diabetes mellitus between one-step and two-step method among Thai pregnant women: A randomized control trial","authors":"Natthaphon Phoblap,&nbsp;Phudit Jatavan,&nbsp;Theera Tongsong","doi":"10.1111/jdi.14370","DOIUrl":"10.1111/jdi.14370","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To compare the prevalence of GDM and pregnancy outcomes between the one-step and two-step methods of universal screening among Thai pregnant women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A randomized controlled trial was conducted on singleton Thai pregnant women at a gestational age of 24–28 weeks. They were randomly assigned to either the one-step method group (a universal 75-gm 2-h oral glucose tolerance test: OGTT) or the two-step method group (a universal 50-gm oral glucose challenge test followed by a 100-gm 3-h OGTT). The women received standard antenatal care. The prevalence of GDM and obstetric outcomes were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 143 women meeting the inclusion criteria were randomly allocated into the one-step group (72 cases) and the two-step group (71 cases). The prevalence of GDM was significantly higher in the one-step group than in the two-step group, with rates of 24/73 (33.3%) vs 8/70 (11.3%); <i>P</i> value 0.002; relative risk of 2.96, 95% CI: 1.43–6.14, respectively. Demographic data and maternal and neonatal outcomes were comparable between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The one-step method can markedly increase the prevalence of GDM to nearly three times that of the two-step method, leading to a substantial increase in care costs and burdens without clear benefits. Convincingly, the one-step method as a new approach may not be suitable for universal screening in a busy antenatal care setting, especially in low-resource health centers in developing countries or among populations with a high prevalence of GDM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 4","pages":"728-734"},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational diabetes in early pregnancy is associated with postpartum glucose intolerance: A perspective from the diabetes and pregnancy outcome for mother and baby study in Japan","authors":"Maki Yokoyama,&nbsp;Kei Miyakoshi,&nbsp;Noriyuki Iwama,&nbsp;Hiroshi Yamashita,&nbsp;Ichiro Yasuhi,&nbsp;Maki Kawasaki,&nbsp;Naoko Arata,&nbsp;Shiori Sato,&nbsp;Yuko Imura,&nbsp;Masako Waguri,&nbsp;Haruna Kawaguchi,&nbsp;Naoki Masaoka,&nbsp;Yoshiyuki Nakajima,&nbsp;Yuji Hiramatsu,&nbsp;Takashi Sugiyama,&nbsp;DREAMBee Study Gestational Diabetes Mellitus Group","doi":"10.1111/jdi.14368","DOIUrl":"10.1111/jdi.14368","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To compare perinatal outcomes and postpartum glucose tolerance between women diagnosed with gestational diabetes mellitus (GDM) before 20 weeks of gestation (EGDM) and those diagnosed at or after 24 weeks of gestation (LGDM) in a Japanese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Data were obtained from a prospective GDM registry. Multivariate analysis was conducted to examine the association between the timing of GDM diagnosis (EGDM vs LGDM) and perinatal outcomes (preterm birth, small for gestational age, large for gestational age, pregnancy-induced hypertension, and neonatal hypoglycemia), as well as postpartum glucose intolerance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1,275 mother-infant pairs were analyzed for perinatal outcomes. Of these, 924 women underwent postpartum testing for glucose intolerance. No significant differences in perinatal outcomes were observed between the EGDM and LGDM groups, except that overweight/obese women with EGDM had 2.5-fold higher rate of preterm birth than those with LGDM. Postpartum glucose intolerance was 1.5 times more likely in the EGDM group than in the LGDM group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women with EGDM had a significantly higher risk of postpartum glucose intolerance than those with LGDM, despite similar perinatal outcomes between the two groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"535-542"},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment","authors":"Xuemei Huang,&nbsp;Jiajin Jiang,&nbsp;Li Liu,&nbsp;Yuanyuan Lin,&nbsp;Feng Zhang,&nbsp;Xiaoshan Ling,&nbsp;Haitao Wei,&nbsp;Guangjing Huang,&nbsp;Jinqun Ye,&nbsp;Cen Huang,&nbsp;Jianli Huang,&nbsp;Wenfu Tao,&nbsp;Xinyu Zou","doi":"10.1111/jdi.14371","DOIUrl":"10.1111/jdi.14371","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim/Introduction</h3>\u0000 \u0000 <p>To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels. The primary outcome measure was hemoglobin A1c (HbA1c) level; secondary outcomes included body weight, body mass index (BMI), waist circumference, glycemic control, and biochemical indices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The time in range (TIR) in the intensive treatment group was greater than that in the conventional treatment group (<i>P</i> &lt; 0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (<i>P</i> &gt; 0.05). Compared with the conventional treatment group, diabetes remission rates were significantly greater in the intensive treatment group (<i>P</i> &lt; 0.05). In the intensive treatment group, fasting plasma glucose (FPG), HbA1c, Homeostasis Model assessment of Insulin Resistance (HOMA-IR), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and changes in body weight, BMI, visceral fat area (VFA), and subcutaneous fat area (SFA) decreased significantly (<i>P</i> &lt; 0.05). FPG, HOMA-IR, TG, LDL-c, and changes in body weight, BMI, waist circumference, and VFA were significantly correlated with HbA1c levels (<i>P</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combination of intensive CSII and LCD lifestyle guidance had been improved the remission rate in patients with newly diagnosed type 2 diabetes mellitus.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"426-433"},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Non-classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease”","authors":"Mostafa Javanian,&nbsp;Mohammad Barary,&nbsp;Soheil Bakhshinasab,&nbsp;Soheil Ebrahimpour","doi":"10.1111/jdi.14356","DOIUrl":"10.1111/jdi.14356","url":null,"abstract":"&lt;p&gt;We read with great interest the article titled “Non-classical Monocyte Frequency and Serum Vitamin D3 Levels are Linked to Diabetic Foot Ulcer Associated with Peripheral Artery Disease,” published in your esteemed journal&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. The research highlights the reduced frequency of non-classical monocytes and low vitamin D3 levels in patients with diabetic foot ulcers (DFUs) associated with peripheral artery disease (PAD), shedding light on the potential role of these factors in DFU pathogenesis. We commend the authors for this valuable contribution, but we believe several methodological improvements could further enhance the study's impact.&lt;/p&gt;&lt;p&gt;The study's focus on limited laboratory markers may have overlooked other potential indicators. Additional biomarkers, such as calcium, potassium, uric acid, liver function tests, and indices like the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI), could provide deeper insights into the inflammatory processes at play in DFU patients&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;. This might help better predict poor outcomes.&lt;/p&gt;&lt;p&gt;Although the Meggitt–Wagner classification provided useful data, it lacks a clear focus on vascular involvement. Other classification systems, such as the PEDIS and SINBAD systems, which evaluate factors like perfusion, depth, infection, and ischemia, could offer a more comprehensive assessment of DFUs and their correlation with PAD&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;The study did not explore other medications beyond antidiabetic drugs that patients might have been using, nor did it address the impact of conditions like cancer, hematologic disorders, or autoimmune diseases. These factors can influence immune function and thus alter the study outcomes.&lt;/p&gt;&lt;p&gt;Alcohol consumption was not investigated, despite its known role in DFU outcomes. Additionally, categorizing smoking status into non-smokers, former smokers, and current smokers could provide a clearer picture of its impact on DFU development and progression.&lt;/p&gt;&lt;p&gt;Classifying PAD into mild, moderate, and severe categories and comparing the frequency of non-classical monocytes and vitamin D3 levels across these groups would enrich the analysis, offering more nuanced insights into the relationship between PAD severity and immune response.&lt;/p&gt;&lt;p&gt;The relatively small sample size of the study could limit its statistical power, leading to wider margins of error. A larger cohort would increase the robustness of the findings, ensuring better generalizability and precision&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;In conclusion, while this study makes a significant contribution to our understanding of the relationship between non-classical monocytes, vitamin D3, and DFUs associated with PAD, addressing the outlined limitations would strengthen the findings and their implications. We believe that future studies incorporating these factors could further advance research in this critical area.&lt;/p&gt;&lt;p&gt;The aut","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"350-351"},"PeriodicalIF":3.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}